Seres Stops Enrollment In Melanoma Study, Deprioritizes Further Development
- Seres Therapeutics Inc (NASDAQ: MCRB) and its study partners have voluntarily discontinued further enrollment in the Phase 1 study evaluating SER-401 in metastatic melanoma.
- The company cited challenges related to the pandemic.
- The study was assessing the safety and drug activity of SER-401 or fecal microbiota transplant (FMT) in combination with nivolumab.
- A preliminary analysis of results from 10 subjects indicated that SER-401 was safe and well-tolerated.
- No patients were enrolled in the FMT portion of the study.
- Subjects currently enrolled in the study will complete the study protocol.
- Price Action: MCRB shares gained 0.73% at $19.2 in premarket trading on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: melanoma phase 1Biotech News Health Care Small Cap FDA General
